Skip to content
PreclinicalResearch compoundLimited evidence

1,3‑DMAA

Potent synthetic sympathomimetic stimulant, banned, with serious cardiovascular risk.

StimulantSympathomimeticStimulantPerformanceNorepinephrineDopamine

Pharmacology

ClassStimulant · Performance
Primary targetNorepinephrine and dopamine release stimulation
Targets3 receptor targets
Half-lifeRoughly 8 hours terminal half-life after a single oral dose
OnsetAbout 30-60 minutes after oral intake; morning or early in the day for energy and focus, avoid late dosing
EvidenceLimited evidence
Affected systemsNorepinephrineDopamine

Contents

WHAT IS 1,3-DMAA?

Detailed overview

1,3-DMAA (methylhexanamine, 1,3-dimethylamylamine) is a synthetic alkylamine stimulant once sold in pre-workout and fat-burner supplements. It acts as an indirectly acting sympathomimetic: it promotes the release of norepinephrine and dopamine, hinders their reuptake, and stimulates alpha- and beta-adrenergic pathways, producing transient energy, alertness and appetite suppression. This is accompanied by marked increases in blood pressure and heart rate, and the compound has been linked to several serious, sometimes fatal cardiovascular events. It has been banned from dietary supplements in most countries and is prohibited in sport. This entry is strictly informational and does not encourage use.

Mechanism

Indirect sympathomimetic (NE/dopamine release)

Half-life

About 8 hours after a single oral dose

Legal status

Banned in supplements; WADA-prohibited

Receptor profile

  • Norepinephrine / dopamine releaseStrong
  • Dopamine transporter (DAT)Moderate
  • Alpha- and beta-adrenergic pathways (blood pressure / heart rate)Strong

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • Marked rise in blood pressure, potentially to dangerous hypertensive peaks
  • Racing or irregular heartbeat, sensation of chest tightness
  • Overstimulation, anxiety, tremor and restlessness
  • Sleep disruption if taken in the late afternoon or evening
  • Linked to serious cardiovascular events: heart attack, cerebral hemorrhage, cardiac arrest, occasionally fatal
  • Additive, unpredictable risk when consumed with other stimulants in supplements

Contraindications · 5

  • Any cardiovascular disease, hypertension or arrhythmia: strictly avoid
  • Pregnancy and breastfeeding: avoid
  • May cause a life-threatening hypertensive crisis when combined with MAO inhibitors
  • Do not combine with other stimulants (caffeine, ephedrine, synephrine)
  • Prohibited for competitive athletes: on the WADA list and will cause a doping violation

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

Potent synthetic sympathomimetic stimulant, banned, with serious cardiovascular risk.

Telegram

Have a question about 1,3‑DMAA?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeStimulant
FormulaC7H17N
UpdatedJuly 10, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: July 10, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.